Press Releases

 
Press Releases
  Date Title and Summary View
Apr 28, 2016
REDWOOD CITY, Calif., April 28, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced data from new analyses of studies with Veltassa® (patiromer) for oral suspension were presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings in Boston. "The data presented today demo...
Apr 27, 2016
REDWOOD CITY, Calif., April 27, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that the company will report first quarter 2016 financial results on Wednesday, May 4, 2016, after the close of financial markets. Management will host a conference call and live audio webcast on the same afternoon at...
Apr 25, 2016
ST. GALLEN, Switzerland and REDWOOD CITY, Calif., April 25, 2016 (GLOBE NEWSWIRE) -- Vifor Fresenius Medical Care Renal Pharma Ltd. (VFMCRP), a common company of Galenica and Fresenius Medical Care, and Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that VFMCRP has submitted a Marketing Authorization Application (MAA) t...
Apr 21, 2016
REDWOOD CITY, Calif., April 21, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (NASDAQ:RLYP), a biopharmaceutical company, today announced that new analyses from studies of Veltassa® (patiromer) for oral suspension will be presented at the National Kidney Foundation (NKF) 2016 Spring Clinical Meetings, taking place April 27-May 1 in Boston. Vel...
Apr 20, 2016
REDWOOD CITY, Calif., April 20, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 15, 2016, the compensation committee of the company's board of directors granted 6 new employees options to purchase an aggregate of 17,650 shares of the company's common stock with a per share exercise ...
Apr 6, 2016
REDWOOD CITY, Calif., April 06, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on April 1, 2016 the compensation committee of the company's board of directors granted 3 new employees options to purchase an aggregate of 7,450 shares of the company's common stock with a per share exercise pri...
Mar 17, 2016
REDWOOD CITY, Calif., March 17, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on Mar. 15, 2016, the compensation committee of the company's board of directors granted 4 new employees options to purchase an aggregate of 10,400 shares of the company's common stock with a per share exercise p...
Mar 3, 2016
REDWOOD CITY, Calif., March 03, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP), a biopharmaceutical company, today announced that on Mar. 1, 2016, the compensation committee of the company's board of directors granted 4 new employees options to purchase an aggregate of 17,200 shares of the company's common stock with a per share exercise pr...
Mar 1, 2016
REDWOOD CITY, Calif., March 01, 2016 (GLOBE NEWSWIRE) -- Relypsa, Inc. (Nasdaq:RLYP) today announced that John A. Orwin, president and chief executive officer, will present at the 36th Annual Cowen Health Care Conference on March 8, 2016 at 8:00 a.m. ET. To access the live webcasts and subsequent archived recordings of these presentations, p...
Feb 24, 2016
Relypsa reports encouraging initial demand for VeltassaVeltassa added to CMS 2016 Formulary Reference File and agreements signed with Express Scripts and CVS Caremark, the two largest pharmacy benefit managers in the United StatesRelypsa plans to submit a supplemental New Drug Application (sNDA) by mid-2016 requesting a label change for Veltassa ba...
Page:
1
... NextLast
= add release to Briefcase